Kennondale Capital Management LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 134,445 shares of the company's stock, valued at approximately $508,000. Kennondale Capital Management LLC owned approximately 0.20% of Amylyx Pharmaceuticals as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of AMLX. Blue Trust Inc. raised its stake in Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after purchasing an additional 4,883 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Amylyx Pharmaceuticals in the 4th quarter worth about $56,000. Barclays PLC raised its stake in Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company's stock worth $274,000 after purchasing an additional 40,319 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company's stock worth $455,000 after purchasing an additional 83,048 shares in the last quarter. Finally, FMR LLC raised its stake in Amylyx Pharmaceuticals by 292.0% in the 3rd quarter. FMR LLC now owns 221,001 shares of the company's stock worth $716,000 after purchasing an additional 164,622 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.
Amylyx Pharmaceuticals Stock Down 2.1 %
Shares of NASDAQ:AMLX traded down $0.08 during midday trading on Friday, hitting $3.65. The stock had a trading volume of 1,505,484 shares, compared to its average volume of 1,393,762. The company's 50-day moving average price is $3.51 and its 200-day moving average price is $3.97. The company has a market capitalization of $323.40 million, a P/E ratio of -0.96 and a beta of -0.51. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million for the quarter. Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Amylyx Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $7.33.
Check Out Our Latest Research Report on AMLX
Insider Transactions at Amylyx Pharmaceuticals
In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 11,851 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the completion of the sale, the chief executive officer now directly owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Justin B. Klee sold 7,471 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the sale, the chief executive officer now owns 3,176,788 shares of the company's stock, valued at $12,834,223.52. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,169 shares of company stock worth $97,274 over the last three months. 11.70% of the stock is owned by company insiders.
Amylyx Pharmaceuticals Profile
(
Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Featured Stories
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
